Table 1.
Clinicopathological characteristics of the training and validation cohorts
| Factors | Training cohort (n = 74) | Validation cohort (n = 32) | P value |
|---|---|---|---|
| Age (years, mean ± SD) | 55.15 ± 11.43 | 54.13 ± 12.68 | 0.68 |
| Gender | 0.53 | ||
| Male | 48 | 18 | |
| Female | 26 | 14 | |
| BMI (kg/m2) | 21 ± 3 | 22 ± 3 | 0.12 |
| Preoperative T stage | 0.39 | ||
| 2 | 1 | 0 | |
| 3 | 11 | 2 | |
| 4 | 62 | 29 | |
| Preoperative N status | 0.99 | ||
| 0 | 2 | 1 | |
| 1–3 | 72 | 31 | |
| Preoperative M status | 0.85 | ||
| 0 | 47 | 19 | |
| 1 | 27 | 13 | |
| Postoperative T stage | 0.83 | ||
| 1–2 | 11 | 6 | |
| 3–4 | 63 | 26 | |
| Postoperative N status | 0.06 | ||
| 0 | 35 | 8 | |
| 1–3 | 39 | 24 | |
| Postoperative M status | 0.90 | ||
| 0 | 53 | 24 | |
| 1 | 21 | 8 | |
| Postoperative TNM stage | 0.23 | ||
| 0 | 3 | 3 | |
| 1 | 6 | 1 | |
| 2 | 22 | 5 | |
| 3 | 22 | 15 | |
| 4 | 21 | 8 | |
| AFP (ng/mL) | 9.25 ± 17.79 | 6.48 ± 8.33 | 0.40 |
| CEA (IU/L) | 0.23 | ||
| Normal | 50 | 26 | |
| Elevated | 24 | 6 | |
| CA125 (IU/L) | 0.08 | ||
| Normal | 73 | 29 | |
| Elevated | 1 | 3 | |
| CA199 (IU/L) | 1.00 | ||
| Normal | 64 | 27 | |
| Elevated | 10 | 5 | |
| Operative duration (min) | 349.46 ± 116.47 | 359.22 ± 111.98 | 0.69 |
| Blood transfusion (ml) | 347.92 ± 506.39 | 362.50 ± 458.43 | 0.89 |
| Total number of dissected lymph node | 40.81 ± 18.67 | 44.09 ± 17.77 | 0.40 |
| Number of positive lymph node | 5.27 ± 9.01 | 7.34 ± 10.42 | 0.30 |
| Treatment response | 0.25 | ||
| TRG 1 | 3 | 3 | |
| TRG 2 | 34 | 14 | |
| TRG 3 | 24 | 10 | |
| TRG 4 | 10 | 4 | |
| TRG 5 | 3 | 1 |
Abbreviations: BMI body mass index, PS performance status, AFP alpha-fetoprotein, CEA carcinoembryonic antigen, TRG tumor regression grading